Skip to Content
Merck

HNABTMAG-68K

MILLIPLEX® Human Neuroscience Panel

Configurable Human Amyloid Beta and Tau 4-Plex Panel, allows quantitative multiplex detection of multiple analytes simultaneously

Synonym(s):

Human Neuroscience Protein Multiplex Assay, Luminex® Human Neuroscience Panel, Millipore Human Neuroscience Immunoassay

Sign In to View Organizational & Contract Pricing.

About This Item

UNSPSC Code:
12161503
eCl@ss:
32161000
NACRES:
NA.84

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

200

species reactivity

human

packaging

pkg of 1 ea

manufacturer/tradename

Milliplex®

assay range

accuracy: 109%
(Spike recovery for Aβ1-42)
accuracy: 91%
(Spike recovery for pTau181)
accuracy: 98%
(Spike recovery for tTau)
sensitivity: 1.5 pg/mL
(pTau181; MinDC+2SD)
sensitivity: 10.2 pg/mL
(Aβ1-40; MinDC+2SD)
sensitivity: 14.2 pg/mL
(tTau; MinDC+2SD)
sensitivity: 2.5 pg/mL
(Aβ1-42; MinDC+2SD)
standard curve range: 0.7-500 pg/mL
(pTau181)
standard curve range: 11-8000 pg/mL
(tTau)
standard curve range: 2-2000 pg/mL
(Aβ1-42)
standard curve range: 21-15000 pg/mL
(Aβ1-40)
inter-assay cv: <15%
intra-assay cv: <10%

technique(s)

multiplexing: suitable

input

cerebrospinal fluid(s) (CSF)

detection method

fluorometric (Luminex® xMAP® technology)

shipped in

wet ice

storage temp.

2-8°C

Related Categories

General description

Alzheimer′s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia, affecting approximately 36 million people worldwide. The disease is characterized by two key features: extracellular amyloid β (Aβ) plaques formed from peptides like Aβ1-40 and Aβ1-42, and intracellular neurofibrillary tangles composed of hyperphosphorylated Tau protein. These biomarkers—reduced soluble Aβ1-42, increased total Tau, and phosphorylated Tau in cerebrospinal fluid—serve as critical indicators of the pathological processes underlying neurodegenerative conditions.

Application

MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 4 analytes in human cerebrospinal fluid (CSF).Analytes included: Amyloid beta 1-40 (Aβ40), Amyloid beta 1-42 (Aβ42), Total Tau proteins (tTau), and Phosphorylated Tau Thr181 (pTau181).Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

Features and Benefits

Harness Mutliplexing Efficiency: Simultaneously measure both Aβ40 and Aβ42 in a single assay, accelerating your neurodegenerative disease research while maximizing laboratory throughput.Built-in Reliability: Every kit undergoes rigorous validation to deliver unwavering consistency across batches, giving you the confidence to pursue breakthrough discoveries without questioning your data integrity.Biologically Relevant Results: Our specially formulated serum matrix replicates physiological conditions, ensuring your findings accurately measure the analytes of interest.Complete Research Solution: Eliminate procurement headaches with our comprehensive kit containing all essential components, allowing you to focus on scientific discovery rather than logistical challenges.Accelerate Scientific Impact: Transform precise biomarker measurements into actionable insights that drive forward our understanding of Alzheimer′s disease and related amyloidopathies.

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

Pictograms

Skull and crossbonesEnvironment
GHS06,GHS09

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Skin Sens. 1

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jessica L Hoffman et al.
International review of neurobiology, 148, 169-230 (2019-11-18)
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that represents the most common cause of dementia in the United States. Although the link between alcohol use and AD has been studied, preclinical research has potential to elucidate neurobiological mechanisms that
Mohamed Raâfet Ben Khedher et al.
Alzheimer's & dementia (New York, N. Y.), 7(1), e12124-e12124 (2021-02-05)
In brain, extracellular vesicles (EVs) play an essential role in the neuron-glia interface and ensure the crosstalk between the brain and the periphery. Some studies now link the pathway dysfunction of the EVs to apolipoprotein E gene variant (APOE ε4)
Wencheng Yin et al.
Frontiers in neuroscience, 14, 602642-602642 (2021-01-05)
Alzheimer's disease (AD)-related degenerative decline is associated to the presence of amyloid beta (Aβ) plaque lesions and neuro fibrillary tangles (NFT). However, the precise molecular mechanisms linking Aβ deposition and neurological decline are still unclear. Here we combine genome-wide transcriptional
Grace E Weber et al.
Journal of immunology (Baltimore, Md. : 1950), 204(5), 1111-1118 (2020-01-22)
Individuals with Down syndrome (DS) develop Alzheimer's disease (AD)-related neuropathology, characterized by amyloid plaques with amyloid β (Aβ) and neurofibrillary tangles with tau accumulation. Peripheral inflammation and the innate immune response are elevated in DS. Triggering receptor expressed in myeloid
Charbel Moussa et al.
Journal of neuroinflammation, 14(1), 1-1 (2017-01-15)
Treatment of mild-moderate Alzheimer's disease (AD) subjects (N = 119) for 52 weeks with the SIRT1 activator resveratrol (up to 1 g by mouth twice daily) attenuates progressive declines in CSF Aβ40 levels and activities of daily living (ADL) scores. For this retrospective study
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service